Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the best money-making stocks to buy right now. On February 13, Morgan Stanley trimmed the price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $360 from $408 and reiterated an Equal Weight rating, TheFly reported. In a research note, the analyst said that although near-term pressures exist, the preannounced fourth-quarter revenue and reaffirmed 2026 TTR sales guidance reflect increased confidence in the launch.

On the same day, RBC Capital also reduced its price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $450 from $465 and maintained an Outperform rating. This downward price revision was attributed to near-term headwinds for the company. While acknowledging the company’s strong commercial execution in 2025, the firm noted that Alnylam appears to be a high-quality company capable of achieving its financial targets.

The company’s future will be supported by 80% of the 300,000 global TTR-CM patients who remain undiagnosed, a significant market opportunity that can be seized, the firm noted. With that said, RBC Capital noted that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is targeting growth beyond its TTR franchise to expand into Huntington’s disease, obesity, and HHT treatments.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a Massachusetts-based RNAi therapeutics company specializing in therapeutics based on ribonucleic acid interference. Founded in 2002, the company provides solutions for hypercholesterolemia, primary hyperoxaluria type 1, acute hepatic porphyria, and hATTR, among others.

While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.